The incidence of cancer is rising globally, and is predicted to reach 30 million new cases in 2040, an almost 50% increase compared with 2020.1
Patients with cancer are among the most malnourished patient groups suggesting that nutritional interventions should be an integral part of cancer treatment2. Global nutrition societies, including the American Society for Parenteral and Enteral Nutrition (ASPEN) and European Society for Clinical Nutrition and Metabolism (ESPEN), recommend the use of Oral Nutritional Supplements (ONS) for patients who are malnourished, or at risk of malnutrition, and unable to eat adequately.2,3
Patients with cancer are at high risk of malnutrition, as both the symptoms of the cancer and the side effects of treatment can negatively affect their ability to eat adequately2.
Side effects of cancer treatment can include loss of appetite, taste alterations, dry mouth, mucositis, swallowing difficulties, early satiety and/or abdominal pain. These symptoms should be considered when formulating ONS for patients with cancer for whom certain product features, such as smooth texture, flavour and ease of swallowing and digestion, are as important as nutritional value. High protein content and high caloric density are suitable to address malnutrition, in addition to a nutritionally complete formula that is compliant with regulations. Some brand owners even consider additional ingredients that make the product specifically designed for patients with cancer. For example, studies have shown that anticatabolic and anti-inflammatory ingredients may improve appetite, oral food intake and body weight in patients with cancer.4